Perrigo (PRGO) Change in Account Payables (2013 - 2026)
Perrigo (PRGO) posted quarterly Change in Account Payables of -$35.9 million for Q1 2026, down 598.61% year-over-year from $7.2 million in Q1 2025, and down 915.91% quarter-over-quarter from $4.4 million in Q4 2025.
Perrigo (PRGO) Change in Account Payables (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has reported Change in Account Payables for 14 consecutive years, with -$35.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 598.61% year-over-year to -$35.9 million; the TTM figure through Mar 2026 stood at -$71.8 million (down 191.93% YoY), while the FY2025 annual figure was -$28.7 million, down 152.95% from the prior year.
- Change in Account Payables declined to -$35.9 million in Q1 2026 per PRGO's latest filing, from $4.4 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $72.6 million in Q2 2022 and bottomed at -$39.0 million in Q3 2023.
- Historically, Change in Account Payables has averaged $1.4 million across 5 years, with a median of -$13.2 million in 2025.
- Annual changes were most pronounced in 2022 — Change in Account Payables surged 2068.0% — and 2026, when it sank 598.61%.
- Perrigo's Change in Account Payables stood at $54.2 million in 2022, then slumped by 50.18% to $27.0 million in 2023, then soared by 118.89% to $59.1 million in 2024, then slumped by 92.55% to $4.4 million in 2025, then plunged by 915.91% to -$35.9 million in 2026.
- Business Quant data shows PRGO's Change in Account Payables at -$35.9 million in Q1 2026, $4.4 million in Q4 2025, and -$13.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -53.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -143.74 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -21.20 Mn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Perrigo | 1.98 Bn | 1.58 Bn | 313.90 Mn | -30.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | -30.90 Mn |
| Jun 27, 2026 | -30.90 Mn |
| Mar 28, 2026 | -35.90 Mn |
| Mar 28, 2026 | -35.90 Mn |
| Dec 31, 2025 | 4.40 Mn |
| Dec 31, 2025 | 4.40 Mn |
| Sep 27, 2025 | -13.20 Mn |
| Sep 27, 2025 | -13.20 Mn |
| Jun 28, 2025 | -27.10 Mn |
| Jun 28, 2025 | -27.10 Mn |
| Mar 29, 2025 | 7.20 Mn |
| Mar 29, 2025 | 7.20 Mn |
| Dec 31, 2024 | 59.10 Mn |
| Dec 31, 2024 | 59.10 Mn |
| Sep 28, 2024 | -18.80 Mn |
| Sep 28, 2024 | -18.80 Mn |
| Jun 29, 2024 | 30.60 Mn |
| Jun 29, 2024 | 30.60 Mn |
| Mar 30, 2024 | -16.70 Mn |
| Mar 30, 2024 | -16.70 Mn |